Vernon Rayford, MD
Internal Medicine · Tupelo, MSNPI 1053548545
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Insulet Corporation accounts for 85.4% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $6,477, more than ten times the $49 reported in 2019. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $98.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$6K
- AbbVie$172
- Lilly USA, LLC$114
- Pfizer$96
- La Jolla Pharmaceutical Company$72
- Otsuka Pharmaceutical Development & Commercialization, Inc.$60
- plus $558 from 21 others
What the payments were for
- Consulting fees$1,50020%
- Speaking & faculty fees$3,00141%
- Travel & lodging$1,68223%
- Food & beverage$1,18016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 14 | $6,291 |
| AbbVie | 9 | $172 |
| Lilly USA, LLC | 8 | $114 |
| Pfizer | 7 | $96 |
| La Jolla Pharmaceutical Company | 4 | $72 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $60 |
| Novartis | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Boehringer Ingelheim | 2 | $44 |
| Abbott | 2 | $37 |
| Boston Scientific | 1 | $36 |
| Amgen | 2 | $29 |
| Novo Nordisk | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Medtronic | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Merck | 1 | $22 |
| Bayer | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$6,105
How this compares
$7,363 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $55,118 |
| OzempicSemaglutide | 27 | $48,426 |
| Xtampza ErOxycodone Myristate | 18 | $24,642 |
| FarxigaDapagliflozin Propanediol | 19 | $15,111 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 355 | $7,876 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 106 | $2,415 |
| SynthroidLevothyroxine Sodium | 20 | $2,199 |
| Gabapentin | 73 | $1,576 |
| Pregabalin | 41 | $1,439 |
| Tramadol Hcl | 105 | $1,019 |
| Omeprazole | 60 | $999 |
| Metoprolol Succinate | 46 | $729 |
| Rosuvastatin Calcium | 64 | $715 |
| Ondansetron OdtOndansetron | 23 | $698 |
| Esomeprazole Magnesium | 15 | $689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $55,11847 claims |
| Novo NordiskOzempic | $29 | $48,42627 claims |
| AstraZenecaFarxiga | $13 | $15,11119 claims |
| AbbVieSynthroid | $172 | $2,19920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Tupelo
- Jonathan BlossomTupelo$11K
- Pami TaylorTupelo$10K
- Henry BolerTupelo$7K
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.